JPI-547 + gemcitabine + nab-paclitaxel

JPI-547 + gemcitabine + nab-paclitaxel is an experimental combination regimen for the treatment of advanced solid tumors, including pancreatic cancer. JPI-547 is a novel oral small molecule dual inhibitor of PARP1/2 (Poly [ADP-ribose] polymerase 1 and 2) and tankyrase 1/2 (TNKS1/2), developed for targeting homologous recombination repair (HRR)-deficient tumors and tumors with Wnt pathway activation. Its mechanism includes strong inhibition of PARP catalytic activity and disruption of Wnt signaling via tankyrase inhibition, resulting in compromised DNA repair and anti-proliferative effects[1][3][5]. When combined with gemcitabine, a nucleoside analog that inhibits DNA synthesis, and nab-paclitaxel, an albumin-bound microtubule stabilizing agent, the combination exerts synergistic antitumor effects. Nab-paclitaxel enhances drug delivery via albumin-mediated mechanisms, while gemcitabine interferes with DNA replication[2][4][6]. Early clinical and preclinical evidence suggests this combination may improve responses in pancreatic and other solid tumors, especially those resistant to conventional PARP inhibitors[1][5].

Other names

nab-paclitaxelalbumin-bound paclitaxelgemcitabine hydrochloride